Search: onr:"swepub:oai:gup.ub.gu.se/267824" >
Inhibition of gamma...
Inhibition of gamma-Secretase Leads to an Increase in Presenilin-1
-
Sogorb-Esteve, A. (author)
-
Garcia-Ayllon, M. S. (author)
-
Llansola, M. (author)
-
show more...
-
Felipo, V. (author)
-
- Blennow, Kaj, 1958 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi,Institute of Neuroscience and Physiology
-
Saez-Valero, J. (author)
-
show less...
-
(creator_code:org_t)
- 2017-08-16
- 2018
- English.
-
In: Molecular Neurobiology. - : Springer Science and Business Media LLC. - 0893-7648 .- 1559-1182. ; 55:6, s. 5047-5058
- Related links:
-
https://link.springe...
-
show more...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- gamma-Secretase inhibitors (GSIs) are potential therapeutic agents for Alzheimer's disease (AD); however, trials have proven disappointing. We addressed the possibility that gamma-secretase inhibition can provoke a rebound effect, elevating the levels of the catalytic gamma-secretase subunit, presenilin-1 (PS1). Acute treatment of SH-SY5Y cells with the GSI LY-374973 (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester, DAPT) augments PS1, in parallel with increases in other gamma-secretase subunits nicastrin, presenilin enhancer 2, and anterior pharynx-defective 1, yet with no increase in messenger RNA expression. Over-expression of the C-terminal fragment (CTF) of APP, C99, also triggered an increase in PS1. Similar increases in PS1 were evident in primary neurons treated repeatedly (4 days) with DAPT or with the GSI BMS-708163 (avagacestat). Likewise, rats examined after 21 days administered with avagacestat (40 mg/kg/day) had more brain PS1. Sustained gamma-secretase inhibition did not exert a long-term effect on PS1 activity, evident through the decrease in CTFs of APP and ApoER2. Prolonged avagacestat treatment of rats produced a subtle impairment in anxiety-like behavior. The rebound increase in PS1 in response to GSIs must be taken into consideration for future drug development.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
Keyword
- Alzheimer's disease
- Presenilin-1
- gamma-Secretase inhibitor
- Therapy
- amyloid precursor protein
- c-terminal fragment
- alzheimers-disease
- cerebrospinal-fluid
- a-beta
- neuropsychiatric symptoms
- avagacestat
- bms-708163
- motor coordination
- peptide production
- drug development
- Neurosciences & Neurology
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database